Nasal mucoadhesive delivery systems of the anti-parkinsonian drug, apomorphine: Influence of drug-loading on in vitro and in vivo release in rabbits

International Journal of Pharmaceutics

Volumn 181, Issue 1, 1999, Pages 125-138

  Ugwoke, Michael Ikechukwu ^a   Sam, Exaud ^a   Van Den Mooter, Guy ^a   Verbeke, Norbert ^a   Kinget, Renaat ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Apomorphine; Carbopol; Controlled release; Nasal drug delivery; Parkinson's disease; Polycarbophil

Indexed keywords

APOMORPHINE; CARBOMER; POLYCARBOPHIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INTRANASAL DRUG ADMINISTRATION; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RABBIT;

ABSORPTION; ACRYLATES; ACRYLIC RESINS; ADHESIVENESS; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIPARKINSON AGENTS; APOMORPHINE; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; MALE; NASAL MUCOSA; RABBITS;

EID: 0032923876     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00018-6     Document Type: Article

References (38)

1. BF Goodrich, 1997. Product information provided by BF Goodrich. Cleveland, OH, USA.
2. Ch'ng H.S., Park H., Kelly P., Robinson J.R. Bioadhesive polymers as platforms for oral controlled drug delivery II: synthesis and evaluation of some swelling, water-insoluble bioadhesive polymers. J. Pharm. Sci. 74:1985;399-405.
3. Chaudhuri K.R., Clough C. Subcutaneous apomorphine in Parkinson's disease: Effective yet underused. Br. Med. J. 316:1998;641.
4. Chien Y.W. Novel Drug Delivery Systems. 1992;Marcel Dekker, New York.
5. Corboy D.L., Wagner M.L., Sage J.I. Apomorphine for motor fluctuation and freezing in Parkinson's disease. Ann. Pharmacother. 29:1995;282-288.
6. Dittigen M., Durrani M., Lehmann K. Acrylic polymers, a review of pharmaceutical applications. Stp Pharma. 7:1997;403-437.
7. Edsman K., Carlfors J., Harju K. Rheological evaluation and ocular contact time of some carbomer gels for ophthalmic use. Int. J. Pharm. 137:1996;233-241.
8. Elgindy N.A. Molecular entrapment of cationic drugs by Carbopol 934. Can. J. Pharm. Sci. 11:1976;32-34.
9. Filipovic-Grcic J., Jalsenjak I. Microspheres of human serum albumin with barbiturates: Effect of drug partition coefficient on preparation and release. J. Pharm. Pharmacol. 45:1992;394-399.
10. French D.L., Himmelstein K.J., Manger J.W. Physicochemical aspects of controlled release of substituted benzoic and naphtoic acids from carbopol gels. J. Control. Release. 37:1995;281-289.
11. Gander B., Gurny R., Doelker E., Peppas N.A. Crosslinked poly(alkylene oxides) for the preparation of controlled release micromatrices. J. Control. Release. 5:1988;271-283.
12. Gunder W., Lippold B.H., Lippold B.C. Release of drugs from ethyl cellulose microcapsules (diffusion pellets) with pore formers and pore fusion. Eur. J. Pharm. Sci. 3:1995;203-214.
13. Harris A.S., Ohlin M., Svensson E., Lethagen S., Nilsson I.M. Effect of viscosity on the pharmacokinetics and biological response to intranasal desmopressin. J. Pharm. Sci. 78:1989;470-471.
14. Hosny E.A. Polycarbophil as a controlled release matrix. Int. J. Pharm. 98:1993;235-238.
15. Illum L., Jorgensen H., Bisgaard H., Krogsgaard O., Rossing N. Bioadhesive microspheres as a potential nasal drug delivery system. Int. J. Pharm. 39:1987;189-199.
16. Kapoor R., Turjanski N., Frankel J.P., Kleedorfer B., Lees A., Stern G. Intranasal apomorphine: a new treatment in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 53:1990;1015.
17. Merck Index, 1983. Tenth edition. Merck & Co., NJ, USA.
18. Morimoto K., Morisaka K. In vitro release and rectal absorption of barbital and aminopyrine from aqueous polyacrylic acid gel. Drug Dev. Ind. Pharm. 13:1987;1293-1305.
19. Mortazavi S.A. An in vitro assessment of mucus/mucoadhesive interactions. Int. J. Pharm. 124:1995;173-182.
20. Nagai T., Nishimoto Y., Nambu N., Suzuki Y., Sekine K. Powder dosage form of insulin for nasal administration. J. Control. Release. 1:1984;15-22.
21. Nagai T. Adhesive topical drug delivery systems. J. Control. Release. 2:1985;121-134.
22. Neau S.H., Chou M.Y., Durrani M.J. Fabrication and characterization of extruded and spheronized beads containing carbopol 974P, NF resin. Int. J. Pharm. 131:1996;47-55.
23. Okada J., Masuyama Y., Kondo T. An analysis of first-order release kinetics from albumin microspheres. J. Microencapsulation. 9:1992;9-18.
24. Park H., Robinson J.R. Physico-chemical properties of water insoluble polymers important to mucin/epithelial adhesion. J. Control. Release. 2:1985;47-57.
25. Peppas N.A., Ponchel G., Duchene D. Bioadhesive analysis of controlled-release systems. II. Time dependent bioadhesive stress in poly(acrylic acid)-containing systems. J. Control. Release. 5:1985;143-149.
26. Ponchel G., Touchard F., Duchene D., Peppas N.A. Bioadhesive analysis of controlled-release systems. I. Fracture and interpenetration analysis in poly(acrylic acid)-containing systems. J. Control. Release. 5:1985;121-141.
27. Ponchel G., Touchard F., Wouessidjewe D., Duchene D., Peppas N.A. Bioadhesive analysis of controlled-release systems. III. Bioadhesive and release behaviour of metronidazole-containing poly(acrylic acid)-hydroxypropyl methylcellulose systems. Int. J. Pharm. 38:1987;65-70.
28. Provasi D., De Ascentiis A., Minutello A., Colombo P., Catellani D.L. Nasal powders of progesterone: manufacturing and bioavailability. Eur. J. Pharm. Biopharm. 40:1994;223-227.
29. Ritger P.L., Peppas N.A. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J. Control. Release. 5:1987;23-36.
30. Sam E., Augustijns P., Verbeke N. Stability of apomorphine in plasma and its determination by high-performance liquid chromatography with electrochemical detection. J. Chromatogr., B. 658:1994;311-317.
31. Sam E., Jeanjean A.P., Maloteaux J.M., Verbeke N. Apomorphine pharmacokinetics after intranasal and subcutaneous application. Eur. J. Drug Metab. Pharmacokinet. 20:1995;27-33.
32. See N.A., Russell J., Connors K.A., Bass P. Adsorption of inorganic ions to polycarbophil as a means of sustained release dosage formulation. Pharm. Res. 4:1987;244-247.
33. Tobyn M.J., Johnson J.R., Dettmar P.W. Factors affecting in vitro gastric mucoadhesion II. Physical properities of polymers. Eur. J. Pharm. Biopharm. 42:1996;56-61.
34. Ugwoke M.I., Verbeke N., Kinget R. Microencapsulation of apomorphine HCl with gelatin. Int. J. Pharm. 148:1997;23-32.
35. Ugwoke, M.I., Sam, E., Van Den Mooter, G., Verbeke, N., Kinget, R., 1998. Eur. J. Pharm. Sci. (submitted).
36. van Laar T., Jansen E.N.H., Essink A.W.G., Neef C. Intranasal apomorphine in parkinsonian on-off fluctuations. Arch. Neurol. 49:1992;482-484.
37. Vandelli M.A., Forni F., Coppi G., Cameroni R. The effect of the crosslinking time period upon the drug release and dynamic swelling of gelatin microspheres. Pharmazie. 46:1991;866-869.
38. Vidgren P., Vidgren M., Arppe J., Hakuli T., Laine E., Paronen P. In vitro evaluation of spray-dried mucoadhesive microspheres for nasal administration. Drug Dev. Ind. Pharm. 18:1992;581-597.